CombiMatrix Reports Preliminary Quarterly Growth in Prenatal Testing Volumes of 124% for First Quarter

CombiMatrix Reports Preliminary Quarterly Growth in Prenatal Testing Volumes
of 124% for First Quarter

Company Expanding Technology Offerings to Continue to Capture Market Share

IRVINE, Calif., April 4, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing
services for developmental disorders and cancer diagnostics, today announced
that it expects to report record volumes of prenatal testing in the first
quarter ended March 31, 2013. Preliminary quarterly growth rates of 124
percent over the first quarter of 2012 were achieved for billable prenatal

The continued rapid growth in prenatal testing is the result of CombiMatrix's
strategic shift in mid-2012 to focus its commercial resources primarily on the
prenatal molecular diagnostic testing markets, where the Company believes that
chromosomal microarray analysis (CMA) is becoming the standard of care. This
strategy is supported by a pair of National Institute of Health-sponsored
studies published in the New England Journal of Medicine in late 2012, which
favored CMA over traditional karyotyping for genetic prenatal diagnosis and
genetic evaluation of stillbirths. Many experts believe that these
publications marked the onset of a paradigm shift toward CMA. CombiMatrix is
the only publicly-traded company that specializes in CMA.

The Company also announced that it was expanding its technology offerings to
continue to capture market share and serve the expanding volumes. By recently
incorporating Single Nucleotide Polymorphisms (SNPs) in its array testing, the
Company has significantly expanded its ability for studying variations between
whole genomes, which is crucial in providing resolution to its customers.

"We have been setting internal growth records since we refocused our
commercial strategy, and now we are expanding our lab capabilities to realize
our goal of being a best-of-class prenatal technology lab," said CEO Mark
McDonough. "With the technologies to match any lab and the focus of our new
prenatal strategy, we anticipate continued strong progress throughout 2013 and

Overall billable testing volumes at the Company, including its de-emphasized
oncology segment, were also up strongly in the period, growing 25 percent in
the quarter over 2012.CombiMatrix expects to report its operating results in
early May, 2013 and file its quarterly report for 2013 on Form 10-Q in
mid-May, 2013.The Company will issue a press release and hold an investor
conference call to discuss results.

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix
Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory
which offers DNA-based testing services to the prenatal, pediatric and
oncology markets.The Company performs genetic testing utilizing Microarray,
FISH, PCR and G-Band Chromosome Analysis.CMDX offers prenatal and pediatric
testing services for the detection of abnormalities of genes at the DNA level
beyond what can be identified through traditional technologies.CMDX was also
the first commercial clinical laboratory in the United States to make
comprehensive DNA-based genomic analysis of solid tumors, including breast,
colon, lung, prostate and brain tumors, available to oncology patients and
medical professionals.Additional information about CMDX is available at or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995.These statements are based upon our current expectations, speak only
as of the date hereof and are subject to change.All statements, other than
statements of historical fact included in this press release, are
forward-looking statements.Forward-looking statements can often be identified
by words such as "anticipates," "expects," "intends," "plans," "goal,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "could," "potential," "continue," "ongoing," "objective," similar
expressions, and variations or negatives of these words and include, but are
not limited to, statements regarding the advantages and efficacy of CMA over
standard karyotyping, the market momentum for CMA, the impact of our CMA focus
on market share, and our preliminary report of prenatal testing volumes.These
forward-looking statements are not guarantees of future results and are
subject to risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in any
forward-looking statement.The risks and uncertainties referred to above
include, but are not limited to:the risk that our final reported prenatal
testing volumes are different from this preliminary report; market acceptance
of CMA as a preferred method over karyotyping; the rate of transition to CMA
from karyotyping; our ability to successfully expand the base of our customers
and strategic partners, add to the menu of our diagnostic tests in both of our
primary markets, develop and introduce new tests and related reports, optimize
the reimbursements received for our testing services, and increase operating
margins by improving overall productivity and expanding sales volumes; our
ability to successfully accelerate sales, allow access to samples earlier in
the testing continuum, steadily increase the size of our customer rosters in
both developmental medicine and oncology; our ability to attract and retain a
qualified sales force; rapid technological change in our markets; changes in
demand for our future products; legislative, regulatory and competitive
developments; general economic conditions; and various other factors.Further
information on potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q,
and in other filings with the Securities and Exchange Commission.We undertake
no obligation to revise or update publicly any forward-looking statements for
any reason, except as required by law.

CONTACT: Company Contact:
         Mark McDonough
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
         Investor Relations Contact:
         John Baldissera
         BPC Financial Marketing
         Tel (800) 368-1217
         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300

CombiMatrix Corporation
Press spacebar to pause and continue. Press esc to stop.